Jade Biosciences, Inc. JBIO
16.40 USD +0.80 (+5.13%)
At closeNov 10, 2026, 4:38 PM EST
16.40 0.00 0.00%
After hours · Nov 10, 4:38 PM ET
15.26 Day range 16.56
8.95 52-week range 28.00
- YTD
- +6.29%
- 1 year
- +76.72%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
globenewswire.com Jade Biosciences to Participate in Upcoming Conferences SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
benzinga.com BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target BTIG analyst Julian Harrison reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $77 price target.
globenewswire.com Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026 EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026 JUNIPER Phase 2 Trial-in-Progress poster…
benzinga.com Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $47 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
seekingalpha.com Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
globenewswire.com Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β…
defenseworld.net Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat reports.…
seekingalpha.com Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
globenewswire.com Jade Biosciences to Participate in Upcoming Conferences SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
seekingalpha.com Jade Biosciences: Duration Is The Real Product Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101…
benzinga.com Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47 Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $45 to $47.
benzinga.com Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 11.63 percent increase over losses of…
globenewswire.com Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical…
globenewswire.com Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
globenewswire.com Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday after a lower close on Wednesday, as the Nasdaq 100,…
benzinga.com Ciena, Docusign And 3 Stocks To Watch Heading Into Thursday Stocks to watch: CIEN, DOCU, LULU, report earnings today. MRAAF introduces world's first 100Vdc 2.2μF chip MLCC for auto safety.
globenewswire.com Jade Biosciences Announces Pricing of Public Offering of Common Stock SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
globenewswire.com Jade Biosciences Announces Proposed Underwritten Public Offering SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
marketbeat.com Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company's plan to advance the…
seekingalpha.com Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
benzinga.com Why Is Jade Biosciences Stock Trading Lower On Monday? Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin A nephropathy (IgAN), showing substantial and sustained reductions in immunoglobulin A (IgA), a…
benzinga.com Taylor Morrison Home Surges On Berkshire Hathaway Acquisition, Joins Elmet Group And Other Big Stocks Moving Higher In Monday's Session U.S. stock futures up, Nasdaq surges 0.35%, with Taylor Morrison's buyout announcement. Other pre-market gainers include ELMT, PURR, and SPCE.
globenewswire.com Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
globenewswire.com Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
globenewswire.com Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
benzinga.com Micron To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratings on analyst ratings page.
benzinga.com This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday 
benzinga.com Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket